Lifileucel versus Nivolumab plus Ipilimumab (NIVO+IPI) in anti-PD1 resistant advanced melanoma: An Indirect Comparison of Survival Outcomes between C-144-01 and SWOG-S1616 (ESMO-IO 2026) - Oct 25, 2026 - Abstract #117P; Pres time: Dec 14, 2026; 05:30 PM - 06:30 PM; Location: Churchill Room; No abstract available
Metastases • Melanoma • Oncology • Solid Tumor
|
|
Paolo A. Ascierto; Oguzhan Alagoz; Murat Kurt; Daniel Olson; Josh Wang; Martijn S. Bijker; Brian Gast man; Yan Xing; Christoffer Gebhardt
|